4D Molecular Therapeutics (NASDAQ:FDMT) Hits New 12-Month High – What’s Next?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s share price hit a new 52-week high during trading on Monday . The stock traded as high as $12.55 and last traded at $12.4290, with a volume of 271845 shares trading hands. The stock had previously closed at $11.60.

Analyst Ratings Changes

Several analysts recently weighed in on FDMT shares. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Chardan Capital restated a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Jefferies Financial Group reiterated a “buy” rating and set a $21.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Finally, The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.88.

4D Molecular Therapeutics Price Performance

The company’s fifty day simple moving average is $9.58 and its 200-day simple moving average is $9.14. The firm has a market capitalization of $681.73 million, a PE ratio of -5.11 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. As a group, equities research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current fiscal year.

Insider Transactions at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of the stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the sale, the insider directly owned 942,485 shares in the company, valued at approximately $9,867,817.95. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the sale, the insider directly owned 8,617 shares of the company’s stock, valued at approximately $103,404. This represents a 53.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 126,478 shares of company stock valued at $1,338,369. 7.90% of the stock is currently owned by company insiders.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC grew its position in 4D Molecular Therapeutics by 164.4% during the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock worth $34,726,000 after purchasing an additional 2,882,508 shares during the last quarter. State Street Corp raised its holdings in shares of 4D Molecular Therapeutics by 197.5% in the fourth quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after buying an additional 1,785,106 shares during the last quarter. RA Capital Management L.P. lifted its stake in shares of 4D Molecular Therapeutics by 23.9% during the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock worth $42,399,000 after buying an additional 1,090,000 shares during the period. Adage Capital Partners GP L.L.C. grew its holdings in shares of 4D Molecular Therapeutics by 605.8% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after buying an additional 1,060,156 shares during the last quarter. Finally, Evergreen Quality Fund GP Ltd. purchased a new stake in shares of 4D Molecular Therapeutics during the fourth quarter valued at $7,136,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.